Full Press Release Details
INDIANAPOLIS , Aug. 22, 2019 /PRNewswire/ -- A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (NYSE: LLY ) in a claim filed by Adocia S.A. over the companies' prior collaboration on a rapid-acting insulin. The panel of three arbitrators ruled that Lilly acted appropriately regarding Adocia's intellectual property, and while they denied Lilly's smaller counterclaim, ruled that Lilly is not liable for damages.
Lilly and Adocia signed a collaboration agreement in December 2014 . Lilly terminated the agreement and discontinued future development, manufacturing, and commercialization related to the program in January 2017 .
About Eli Lilly and Company Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom . C-LLY
| Refer to: | Scott MacGregor; [email protected] ; +1 317-440-4699 (Media) |
| Kevin Hern; [email protected] ; +1 317-277-1838 (Investors) |
SOURCE Eli Lilly and Company